Chronic myelomonocytic leukemia (CMML) is a blood cancer that sits at the crossroads of two disease categories: myelodysplastic syndromes, where the bone marrow makes defective blood cells, and myeloproliferative neoplasms, where the marrow overproduces certain cell types. Treatment depends heavily on which subtype you have, your individual risk profile, and whether you’re a candidate for a stem cell transplant. There is no single standard path, but a framework built around risk scoring, symptom control, hypomethylating agents, and transplant timing guides most decisions.
How CMML Is Classified
CMML is defined by a persistent elevation of monocytes, a type of white blood cell, in the bloodstream. The percentage of immature cells called blasts in the blood and bone marrow determines the subtype. CMML-0 has the fewest blasts, CMML-1 has a moderate number, and CMML-2 has the highest. Higher blast counts signal a greater risk of the disease transforming into acute myeloid leukemia (AML).
Beyond blast counts, CMML is also split into two clinical phenotypes. Dysplastic CMML features low blood counts and poorly functioning cells. Proliferative CMML features high white blood cell counts and often an enlarged spleen. This distinction matters because the two types can behave differently and respond to different initial strategies.
Genetic Mutations That Shape Prognosis
Molecular testing has become central to managing CMML. Three mutations dominate the landscape: TET2 (found in roughly 46% to 60% of patients), ASXL1 (around 40% to 47%), and SRSF2 (approximately 45% to 50%). These aren’t just diagnostic footnotes. They directly influence survival and guide treatment intensity.
ASXL1 mutations carry a clear negative impact on survival. TET2 mutations, on the other hand, appear favorable, but only when ASXL1 is not also mutated. In a study of 175 CMML patients, those with a TET2 mutation and no ASXL1 mutation had a median survival of 38 months. Patients with both mutations had a median survival of just 16 months. Those with neither mutation fell in between at 19 months. This interaction between the two genes means testing for both is essential, not optional. Other mutations that factor into risk include RUNX1, NRAS, and SETBP1.
Risk Stratification Guides Every Decision
Several scoring systems exist to estimate how aggressive the disease is. The CPSS-Mol score incorporates genetic mutations alongside traditional factors like blood counts and chromosomal abnormalities, and it is particularly useful for predicting the risk of transformation to AML. Other models like the GFM score flag anemia, high white cell counts, low platelets, age over 65, and ASXL1 mutations as markers of shorter survival.
No single scoring system is perfect. The CPSS-Mol and WHO subtypes both correlate significantly with overall survival, but different models have different strengths. Clinicians often use more than one to build a fuller picture. What matters for patients is that the risk category, ranging from very low to very high, directly determines how urgently treatment should begin and whether transplant should be pursued.
Hypomethylating Agents as First-Line Therapy
For patients who need active treatment beyond supportive care, hypomethylating agents (HMAs) are the primary option. These drugs work by reactivating genes that the cancer has silenced, nudging abnormal cells back toward normal behavior or triggering their death. About 50% of patients respond to these therapies, which means a significant number do not, and identifying who will benefit remains a challenge.
The two main HMAs are azacitidine and decitabine. Both are traditionally given as injections over multiple days. When patients respond, the median duration of that response is approximately 13 months with azacitidine and 9 to 10 months with decitabine. Responses can take time to emerge. A minimum of four treatment cycles is typically needed before concluding the drug isn’t working, and some patients require longer.
An oral formulation combining decitabine with cedazuridine (a companion drug that prevents decitabine from being broken down in the gut) is FDA-approved for CMML. The tablet is taken once daily for five days of each 28-day cycle, on an empty stomach, with no food two hours before or after each dose. This oral option eliminates the need for clinic visits for injections during treatment days, which can meaningfully improve quality of life over months or years of therapy.
Managing Proliferative Symptoms
Patients with proliferative CMML, those with high white cell counts and enlarged spleens, often need cytoreduction to bring cell counts under control. Hydroxyurea is the drug of choice for this purpose. A landmark trial used a starting dose of 1,000 mg per day to manage proliferative disease. Hydroxyurea doesn’t alter the underlying disease biology, but it controls symptoms like fatigue from an overactive marrow and discomfort from splenomegaly. It’s often used as a bridge, keeping the disease manageable while longer-term treatment strategies are planned.
When Stem Cell Transplant Is the Goal
Allogeneic stem cell transplant, receiving donor stem cells, is the only treatment that offers a realistic chance of curing CMML. It is reserved for patients who are physically fit enough to tolerate the procedure and whose disease risk justifies the significant toxicity involved.
Timing matters enormously. A large analysis found that patients in the very low or low risk categories (about 62% of those studied) had better outcomes when transplant was delayed 24 to 36 months after diagnosis. Intermediate, high, and very high risk patients (the remaining 38%) benefited from early transplant, ideally within 3 to 6 months of diagnosis. This finding reinforces that transplant timing should be individualized rather than reflexive.
Donor selection has also evolved. Rather than simply choosing the best-matched family member, transplant centers now weigh donor age, overall health, viral exposure history, and other biological factors. The goal is to find the donor whose cells are most likely to engraft successfully while minimizing complications like graft-versus-host disease.
Whether patients need treatment with HMAs before transplant to reduce disease burden remains an open question. The current expert consensus leans toward prioritizing early referral for transplant in patients with aggressive disease features rather than delaying for pretransplant therapy, though this varies by center and individual circumstances.
Supportive Care Throughout Treatment
Regardless of the primary treatment strategy, supportive care is a constant thread. Many CMML patients develop anemia that requires red blood cell transfusions. Erythropoiesis-stimulating agents, drugs that boost the body’s own red blood cell production, can reduce transfusion needs in some patients. For those who become transfusion-dependent, iron overload from repeated transfusions becomes a concern that may need its own management.
Infection risk is elevated because CMML disrupts normal immune cell production and function, even when white blood cell counts appear adequate. Preventive measures against infections are incorporated into care plans, especially during active treatment with HMAs, which can temporarily worsen blood counts before they improve.
Measuring Treatment Response
Evaluating whether treatment is working uses specific benchmarks. Complete remission means blast levels in the bone marrow drop below 5%, hemoglobin rises to at least 10 g/dL, platelets recover above 100,000, and neutrophils exceed 1,000 per microliter with no blasts circulating in the blood. For patients who don’t achieve full remission, hematologic improvement is a meaningful secondary goal: a hemoglobin increase of at least 1.5 g/dL, a platelet increase of at least 30,000, or a doubling of neutrophil counts that reaches at least 500 above baseline. These improvements must last at least eight weeks to count.
Many patients achieve hematologic improvement without ever reaching complete remission, and this still translates to better quality of life and, in some cases, longer survival. The practical takeaway is that treatment success in CMML is not all-or-nothing. Partial responses can be clinically meaningful, especially for patients whose primary burden is transfusion dependence or recurrent infections.